利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

179 records (took 0.02 seconds)

    METHOD OF PROMOTING ERYTHROPOIESIS
    92.
    发明申请
    METHOD OF PROMOTING ERYTHROPOIESIS 审中-公开
    促进红细胞生成的方法

    公开(公告)号：WO99040106A2

    公开(公告)日：1999-08-12

    申请号：PCT/US1999/002648

    申请日：1999-02-08

    IPC: A61K38/00 ,  A61K38/08 ,  A61K38/22 ,  A61P7/06 ,  C07K7/06 ,  C12N5/078 ,  C07K7/00

    CPC classification number: A61K38/085 ,  C12N5/0644 ,  C12N2501/32

    Abstract: The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.

    Abstract translation: 本发明通过加强红细胞生成素诱导的血管紧张素原分化，血管紧张素I（AI），AI类似物，AI片段及其类似物，血管紧张素II类似物，AII片段或类似物来提供增强红细胞生成的方法，化合物，药物组合物和试剂盒 或AIIAT2型2受体激动剂作为治疗辅助剂。 该方法可用于治疗与慢性肾功能衰竭，终末期肾病，肾移植，癌症，艾滋病，化学疗法，放射治疗，骨髓移植和慢性疾病相关的先天性或获得性再发性或发育不全的贫血。

    COMPOSITIONS CONTAINING AN ANGIOTENSIN II ANTAGONIST AND AN ANGIOTENSIN II AGONIST FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION
    94.
    发明申请
    COMPOSITIONS CONTAINING AN ANGIOTENSIN II ANTAGONIST AND AN ANGIOTENSIN II AGONIST FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION 审中-公开
    含有ANGIOTENSIN II拮抗剂和ANGIOTENSIN II AGONIST的组合物用于治疗溃疡性功能障碍

    公开(公告)号：WO98046266A1

    公开(公告)日：1998-10-22

    申请号：PCT/US1998/005893

    申请日：1998-03-26

    IPC: A61K31/00 ,  A61K31/401 ,  A61K31/4178 ,  A61K38/08 ,  A61K38/55 ,  A61K45/06

    CPC classification number: A61K31/00 ,  A61K31/401 ,  A61K31/4178 ,  A61K38/085 ,  A61K38/553 ,  A61K38/556 ,  A61K45/06

    Abstract: Methods and compositions for treating patients having erectile dysfunction are described. The method involves the step of treating a patient with a combination of an AT1 specific Angiotensin II antagonist and Angiotensin II agonist. Preferably the AT1 specific Angiotensin II antagonist is an AT1 specific Angiotensin II antagonist. The composition is a pharmaceutical composition including an equivalent molecular ratio of an AT1 specific Angiotensin II antagonist and Angiotensin II agonist.

    Abstract translation: 描述了治疗勃起功能障碍患者的方法和组合物。 该方法包括用AT1特异性血管紧张素II拮抗剂和血管紧张素II激动剂的组合治疗患者的步骤。 优选AT1特异性血管紧张素II拮抗剂是AT1特异性血管紧张素II拮抗剂。 该组合物是包含AT1特异性血管紧张素II拮抗剂和血管紧张素II激动剂的当量分子比的药物组合物。

    COMPOSITIONS AND METHOD FOR TREATING BLADDER DYSFUNCTION
    95.
    发明申请
    COMPOSITIONS AND METHOD FOR TREATING BLADDER DYSFUNCTION 审中-公开
    用于治疗刀片功能障碍的组合物和方法

    公开(公告)号：WO98046224A1

    公开(公告)日：1998-10-22

    申请号：PCT/US1998/005886

    申请日：1998-03-26

    IPC: A61K31/00 ,  A61K31/401 ,  A61K31/4178 ,  A61K38/08 ,  A61K38/55 ,  A61K45/06 ,  A61K31/41

    CPC classification number: A61K31/00 ,  A61K31/401 ,  A61K31/415 ,  A61K31/4178 ,  A61K38/085 ,  A61K38/553 ,  A61K38/556 ,  A61K45/06

    Abstract: A method for treating patients having bladder dysfunction is described. The method involves the step of treating a patient with a renin-angiotensin system inhibitor. Preferably the inhibitor is an Angiotensin II antagonist, an ACE inhibitor, or a renin inhibitor. Compositions of a combination of an AT1 specific Angiotensin II antagonist and an Angiotensin II agonist are also described. The compositions are useful for treating bladder dysfunction.

    Abstract translation: 描述了一种治疗膀胱功能障碍的患者的方法。 该方法包括用肾素 - 血管紧张素系统抑制剂治疗患者的步骤。 优选地，抑制剂是血管紧张素II拮抗剂，ACE抑制剂或肾素抑制剂。 还描述了AT1特异性血管紧张素II拮抗剂和血管紧张素II激动剂组合的组合物。 该组合物可用于治疗膀胱功能障碍。

    ANGIOTENSIN IV AND ANALOGS AS REGULATORS OF FIBRINOLYSIS
    96.
    发明申请
    ANGIOTENSIN IV AND ANALOGS AS REGULATORS OF FIBRINOLYSIS 审中-公开
    ANGIOTENSIN IV和模拟物作为纤维蛋白溶解的调节剂

    公开(公告)号：WO1997016201A1

    公开(公告)日：1997-05-09

    申请号：PCT/US1996013804

    申请日：1996-08-27

    Applicant: BRIGHAM & WOMEN'S HOSPITAL ,  WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION

    Inventor： BRIGHAM & WOMEN'S HOSPITAL ,  WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION ,  VAUGHAN, Douglas, E. ,  HARDING, Joseph, W.

    IPC: A61K38/00

    CPC classification number: C07K5/0821 ,  A61K38/085 ,  A61K38/55 ,  C07K5/0804 ,  C07K7/14 ,  C07K16/26

    Abstract: Angiotensin IV (VAL-TYR-ILE-HIS-PRO-PHE), a degradation product of angiotensin II previously thought to be inactive, interacts directly with endothelial cells to induce expression of PAI-1 and thereby to inhibit clot lysis attributable to endogenous t-PA. Moreover, angiotensin IV does not effect substantial physiological changes (vasoconstriction, increased blood pressure, etc.) characteristic of angiotensin II. Fibrinolysis is promoted by reducing the amount or the effect of angiotensin IV. Fibrinolysis is inhibited by providing enhanced angiotensin IV. Methods of screening candidates for antagonizing angiotensin IV are also disclosed.

    Abstract translation: 血管紧张素IV（VAL-TYR-ILE-HIS-PRO-PHE），以前被认为是无活性的血管紧张素II的降解产物与内皮细胞直接相互作用以诱导PAI-1的表达，从而抑制归因于内源性t的凝块溶解 -PA。 此外，血管紧张素IV不影响血管紧张素II特征的显着生理变化（血管收缩，血压升高等）。 通过减少血管紧张素IV的量或作用促进纤维蛋白溶解。 通过提供增强的血管紧张素IV抑制纤维蛋白溶解。 还公开了筛选拮抗血管紧张素IV的候选物的方法。

    THE USE OF DES-ASPARTATE-ANGIOTENSIN I AS AN ANTI-CARDIAC HYPERTROPHIC AGENT
    97.
    发明申请
    THE USE OF DES-ASPARTATE-ANGIOTENSIN I AS AN ANTI-CARDIAC HYPERTROPHIC AGENT 审中-公开
    DES-ASPARTATE-ANGIOTENSIN I作为抗心律失常药物的使用

    公开(公告)号：WO1996037213A1

    公开(公告)日：1996-11-28

    申请号：PCT/SG1996000004

    申请日：1996-05-22

    Applicant: NATIONAL UNIVERSITY OF SINGAPORE ,  SIM, Meng, Kwoon

    Inventor： NATIONAL UNIVERSITY OF SINGAPORE

    IPC: A61K38/08

    CPC classification number: A61K38/085

    Abstract: The use of des-Aspartate-angiotensin I (Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) as an anti-cardiac hypertrophic agent is described. The compound, given either intravenously or orally, prevented the development of experimentally-induced cardiac hypertrophy in rats. Its action was dose-dependent and the maximum anti-cardiac hypertrophic effect was obtained at a dose of (i) 180 mg/day when given intravenously, and (ii) 285 mg/day when given orally.

    Abstract translation: 描述了使用去天冬氨酸血管紧张素I（Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu）作为抗心脏肥大剂。 给予静脉内或口服的化合物阻止了大鼠实验诱导的心脏肥大的发展。 其作用是剂量依赖性的，并且以（i）静脉内给药180mg /天的剂量获得最大的抗心脏肥大效应，和（ii）口服给药时为285mg /天。

    ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION
    99.
    发明申请
    ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION 审中-公开
    ANGIOTENSIN II单独或组合用于治疗高血压

    公开(公告)号：WO2015095535A9

    公开(公告)日：2016-07-14

    申请号：PCT/US2014071186

    申请日：2014-12-18

    Applicant: GEORGE WASHINGTON UNIVERSITY A CONGRESSIONAL CHARTERED NOT FOR PROFIT CORP

    Inventor： CHAWLA LAKHMIR

    IPC: A61K38/08 ,  A61K31/137 ,  A61P9/02

    CPC classification number: A61K38/085 ,  A61K9/0019 ,  A61K31/135 ,  A61K31/137

    Abstract: The present invention relates, e.g., to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-2.0 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.

    Abstract translation: 本发明涉及一种方法，其包括向具有高产出冲击的受试者施用相当于至少约0.2mcg / kg / min的去甲肾上腺素的剂量的血管紧张素II的剂量的儿茶酚胺进行治疗，所述剂量的血管紧张素II对于 将受试者的血压提高到约65mm Hg或更高的平均动脉压（MAP），并且其有效地将维持约65mm Hg的MAP所需的儿茶酚胺的剂量降低至相当于约0.05mm -2.0mcg / kg / min去甲肾上腺素或更少，或相当于约0.05mcg / kg / min去甲肾上腺素或更少。

Patent Agency Ranking